The venom of a wasp native to Brazil could be used in the fight against cancer, according to new University of Leeds research.
The social wasp Polybia paulista protects itself against predators by producing venom known to contain a powerful cancer-fighting ingredient.
The research reveals exactly how the venoms toxin - called MP1 (Polybia-MP1) - selectively kills cancer cells without harming normal cells.
MP1 interacts with fatty molecules, called lipids, that are abnormally distributed on the surface of cancer cells, creating gaping holes that allow molecules crucial for cell function to leak out.
Cancer therapies that attack the lipid composition of the cell membrane would be an entirely new class of anticancer drugs, said Dr Paul Beales, from the School of Chemistry, who co-authored the research.
This could be useful in developing new combination therapies, where multiple drugs are used simultaneously to treat a cancer by attacking different parts of the cancer cells at the same time.
In laboratory tests, the toxin has been shown to inhibit the growth of prostate and bladder cancer cells, as well as multi-drug resistant leukemic cells. However, until now, it was not clear how MP1 selectively destroys cancer cells without harming normal cells.
Co-author, Dr João Ruggiero Neto of São Paulo State University in Brazil, suspects that the reason might have something to do with the unique properties of cancer cell membranes.
He said: Formed in only seconds, these large pores are big enough to allow critical molecules such as RNA and proteins to easily escape cells.
In future studies, the researchers plan to alter MP1s amino acid sequence to examine how the peptides structure relates to its function and further improve the peptides selectivity and potency for clinical purposes.
Understanding the mechanism of action of this peptide will help in translational studies to further assess the potential for this peptide to be used in medicine, said Dr Beales.
As it has been shown to be selective to cancer cells and non-toxic to normal cells in the lab, this peptide has the potential to be safe, but further work would be required to prove that.
The research was supported by the University of Leeds, the European Commission, the Sao Paulo Research Foundation, the Brazilian Council for Scientific and Technological Development, CAPES, and the EPSRC.
The research was published in the Biophysical Journal on 1 September 2015.
Dr Paul Beales is available for interview, contact the University of Leeds press office on 0113 343 4031 or email email@example.com.
Photo credit: Prof. Mario Palma/Sao Paulo State University.
Biophysical Journal, Leite et al.: PE and PS Lipids Synergistically Enhance Membrane Poration by a Host-Defense Peptide with Anticancer Properties http://dx.doi.org/10.1016/j.bpj.2015.07.033